Supporting these caveats, postmortem neuronal tissues of SMA patients intravenously treated with onasemnogene did not show SMN overexpression in neuronal tissues (Thomsen et al., 2021). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.